通过neflamapimod-rasagiline杂交剂准莱维体痴呆症
Claudia Albertini1, Sabrina Petralla2, Francesca Massenzio1
1Department of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Bologna, Italy.
Archiv der Pharmazie
|February 27, 2024
概括
研究人员开发了新的neflamapimod-propargylamine杂交物来治疗勒维体痴呆症 (LBD). 混合4在细胞模型中显示出强大的p38α-MAPK抑制和显著的神经保护,为LBD提供了一个有前途的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 药物发现 药物发现 药物发现
背景情况:
- 莱维体痴呆症 (LBD) 是一种严重的神经退行性疾病,治疗选择有限.
- 作为p38α-MAPK抑制剂的nepflamapimod (1) 显示出与LBD相关的抗神经炎症作用.
- 甲胺是一种神经保护性化合物的类别,具有用于LBD治疗的潜力.
研究的目的:
- 为了合成和评估用于LBD治疗的新型neflamapimod-propargylamine混合物.
- 结合neflamapimod的抗神经炎症特性与propargylamines的神经保护作用.
- 在LBD细胞模型中评估这些混合分子的疗效和安全性.
主要方法:
- 合成内夫拉皮莫德-普拉帕吉胺混合物,特别是化合物3和4.
- 对混合体的p38α-MAPK抑制活性的评估.
- 在基于细胞的测定中评估肝脏和神经毒性.
- 对微质细胞 (N9细胞系) 免疫调节作用的分析.
- 测试神经细胞中抗氧化应激的神经保护作用.
主要成果:
- 该N-甲基-N-propargyl衍生物 (4) 呈现出纳米级p38α-MAPK抑制活性 (IC50 = 98.7 nM).
- 化合物4在高达25μM的度下没有表现出肝或神经毒性.
- 混合4保持了与原始化合物相似的免疫调节特征 (1).
- 在5μM时,化合物4与化合物1相比,对抗氧化应激的神经保护作用优越.
结论:
- 尼夫拉皮莫德-甲胺混合4是一种强效和安全的分子,用于LBD治疗.
- 这种新型混合物有效抑制p38α-MAPK,并提供神经保护.
- 这种化合物代表了利维体痴呆症的有希望的治疗候选者.
相关概念视频
01:24Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268
01:22Alzheimer's Disease: Treatment
189
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
189
01:23Antidepressant Drugs: MAOIs and Other Agents
230
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
230
01:15Parkinson's Disease: Overview
546
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
546
01:37Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K